Healthcare Industry News: vascular access
News Release - July 12, 2010
Theragenics Announces Supply and Reseller Agreement with OncuraUnit of GE to Be a Distributor of TheraSeed® in the U.S. and Canada
BUFORD, Ga.--(HSMN NewsFeed)--Theragenics Corporation (NYSE: TGX ), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Oncura, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds. Oncura is a unit of GE Healthcare. Under the terms of the agreement, Theragenics will be the exclusive palladium-103 seed supplier to Oncura, subject to certain pre-existing vendor agreements, for the treatment of prostate cancer in the U.S. and Canada. The term of the agreement is through May 31, 2013 and provides for additional one-year terms upon mutual agreement of the parties.
“We are pleased to be working with Oncura again,” stated M. Christine Jacobs, Chairman and CEO of Theragenics. “We previously supplied Oncura and its predecessors with TheraSeed® from 2000 through 2005. Reestablishing our relationship with Oncura is a testament to the quality and reliability of Theragenics and TheraSeed® in the brachytherapy industry. Oncura has been a leading brachytherapy supplier since 1991, and they bring a unique understanding of the industry.”
“We are excited to offer our customers our industry-standard iodine-125 based OncoSeedTM and RAPID Strand™ brands, as well as the leading palladium-103 brand in TheraSeed®,” stated Thomas Barker, Urology Product Leader for GE and General Manager of Oncura. “We are pleased to reestablish our relationship with Theragenics who, along with Oncura, is a recognized leader in the advancement of brachytherapy.”
Theragenics Corporation (NYSE: TGX ) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. The brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed® device (www.theraseed.com) and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer. For additional information, call our Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.
Oncura is a unit of GE Healthcare and is an acknowledged world leader in researching, developing and the commercialization of Low Dose Rate (LDR) Brachytherapy. Oncura’s goal is to ensure that all cancer patients should have access to the minimally invasive benefits of brachytherapy when it is a suitable clinical option.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.